The M235T polymorphism in the angiotensinogen gene is not a major risk factor for diabetic nephropathy; a meta-analysis

Bhuneshwar Sahu1, Shashikant Swarnakar2, Henu Kumar Verma3, Thavanati Parvathi Kumara Reddy4, Smaranika Pattnaik5, Bhaskar VKS Lakkakula6

1Department of Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur
2Department of Biochemistry, Late Atal Bihari Vajpayee Memorial Medical College Rajnandgaon (C.G.), India
3Department of Immunopathology, Institute of lungs Biology and Disease, Comprehensive Pneumology Center, Helmholtz Zentrum, 85764 Neuherberg, Munich, Germany
4Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México
5Department of Biotechnology and Bioinformatics, Sambalpur University, Jyoti Vihar, Sambalpur, India

Abstract

Introduction: Diabetic nephropathy (DN) is the leading cause of chronic kidney disease in diabetes patients. The angiotensin AGT M235T gene polymorphism, which is linked to the renin-angiotensin-aldosterone system (RAAS), has been extensively studied in DN patients, but the results are still conflicting. The current study’s goal is to conduct a meta-analysis to assess the relationship between AGT M235T gene polymorphism and DN susceptibility.

Methods: Fourteen case-control studies related to AGT M235T polymorphism and DN were searched using PubMed, Web of Science and Google Scholar databases. Genotype data from the T2DM and T2DN groups were collected from all papers. The pooled odds ratio (OR) and 95 percent confidence interval (95% CI) were calculated employing a random-effects model to assess the relationship.

Results: There were no statistically significant link between AGT M235T and DN risk in dominant (P=0.801, OR: 0.95; 95% CI: 0.66-1.38), allelic (P=0.933, OR: 1.01; 95% CI: 0.75-1.37) and recessive (P=0.374, OR: 1.21; 95% CI: 0.80-1.83) genetic models. Further, the stratified analysis based on ethnicity did not reveal significant link between AGT M235T and DN risk in Asian (Dom OR: 1.07; 95% CI: 0.63-1.82) and the Caucasian populations (Dom OR: 0.77; 95% CI: 0.49-1.21). In all three models, there was a high degree of heterogeneity between studies. Publication bias was not seen.

Conclusion: Our findings suggest that the AGT gene M235T polymorphism does not contribute to DN risk. However, validation of this association will require multi-center and large population-based studies.

Introduction

Diabetic nephropathy (DN) is one of the common microvascular complications in patients with diabetes mellitus, and it is the leading cause of chronic kidney disease (CKD) and renal failure (1). In the past decade, the incidence of DN is increased and now accounting for approximately 50% of all end-stage renal diseases (ESRDs) (2). According to USA Renal Data System, DN was the most common primary diagnosis in 2018 (3). Both type 1 and type 2 diabetes induce changes in glomerulus, tubulointerstitium and vasculature in different kidney compartments (4). Besides, long-standing DM, poor glycemic control and genetic factors are the major risk factors for DN (5). However, despite the belief that genetic factors may have an impact on the DN risk, none of the genes have yet been clearly defined. The advancement of single-nucleotide polymorphism (SNP) technology has resulted in an increase in the number of studies being conducted to investigate the relationship between genetic polymorphism and DN risk (6). A number of candidate genes have been identified, including those involved in the regulation of renin–angiotensin–aldosterone (RAAS) and lipid metabolism (7-9).

Key point

Diabetic nephropathy in diabetes patients is positively correlated with end-stage renal disease (ESRD). Previous evidence has shown that RAAS plays an essential role in the development and progression of DN. The present meta-analysis analysed the association between AGT M235T polymorphism nephropathy in T2DM patients. This meta-analysis indicated that the AGT gene M235T polymorphism does not contribute to DN risk.

Copyright © 2022 The Author(s); Published by Society of Diabetic Nephropathy Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
plays an essential role in the development and progression of DN (10). Recently, some genetic variants such as angiotensin-converting enzyme (ACE) I/D polymorphism, angiotensin II type 1 receptor (AT1R) A1166C (rs5186) gene polymorphism and AGT M235T (rs699) in the RAAS pathway have been significantly associated with the risk of DN (11,12). AGT is a vital component of level II angiotensin, which is a major component of the RAAS. Further, genetic polymorphism in the AGT gene may lead to DN progression in patients with DM.

Several studies have examined the relationship between M235T polymorphism and diabetic nephropathy; however, the results are inconsistent (13-26). Thus, we conducted this meta-analysis to investigate the precise relationship between AGT M235T and diabetic nephropathy.

Materials and Methods

Literature search

A meta-analysis was carried out to investigate the association between DN risk and AGT M235T. In this perspective, MEDLINE, PubMed, EMBASE, Scopus databases, Web of Science, used to conduct analysis using the search keywords of “Angiotensinogen”, “AGT M235T”, “rs699”, “diabetic nephropathy” and “diabetic kidney disease.” All Information was collected up to July 2020.

Inclusion and exclusion criteria

The inclusion and exclusion criteria used in our study were as follows. Inclusion criteria: (a) case-control study design; (b) studies that addressed DN cases and diabetic controls; (c) Studies that assessed the link between AGT M235T and DN risk; (d) detailed genotype methods should be provided for the study. Exclusion criteria: (a) not case-control studies; (b) studies with AGT M235T with T1DM and (c) studies overlapped with any other articles. The names of the first author, year of publication, country, ethnicity, genotyping method and genotype data from the T2DM and T2DN groups were collected.

Statistical analysis

The association between AGT M235T and DN risk was measured in three genetic models (allelic, dominant and recessive) by estimating ORs and corresponding 95% CIs. The Cochran’s Q test and I² values were applied to assess the degree of heterogeneity between studies (27). The results were pooled using a random-effects model. To test the robustness of this meta-analysis, sensitivity analysis was used, which involved removing one study at a time. Begg’s funnel plot and Egger’s test were used to investigate publication bias. Ethnicity based subgroup analysis was performed. All analysis were performed by MetaGenyo web tool (28).

Results

Study characteristics

The flow of the literature search strategy is shown in Figure 1. Based on the systematic search we have identified 14 papers that were analyzing the association between AGT M235T polymorphism nephropathy in T2DM patients (13-26). The essential features of each study and their genotype frequency of AGT M235T polymorphism were depicted in Table 1. The years of publication ranged from 1996 to 2017. Four studies have been deviated from Hardy-Weinberg equilibrium (HWE) in control groups of the AGT M235T polymorphism (14,18,20,23).

Association of AGT M235T polymorphism with susceptibility to diabetic nephropathy

To explore the association between AGT M235T gene polymorphisms with the risk of DN, 14 studies were enrolled. Forest plot and overall pooled effect show the relationship between AGT M235T polymorphism and DN an independent studies in the dominant model (Figure 2). The current meta-analysis shows that there was significant heterogeneity between studies (I² = 73% to 94%). The random-effect model was used to estimate the pooled ORs. The measures of the association between DN and AGT M235T polymorphism were documented in Table 2. Meta-analysis results suggest that there were no statistically significant association between AGT M235T and DN risk in dominant (P = 0.801, OR: 0.95; 95% CI: 0.66-1.38), allelic (P = 0.933, OR: 1.01; 95% CI: 0.75-1.37) and recessive (P = 0.374, OR: 1.21; 95% CI: 0.80-1.83) genetic models. Moreover, subgroup analyses of AGT M235T based on ethnicity did not show a statistically significant association between DN risk in Asian (Dom OR: 1.07; 95% CI: 0.63-1.82) and the Caucasian populations (Dom OR: 0.77; 95% CI: 0.49-1.21).
Sensitivity analysis and publication bias

In sensitivity analysis, there was no significant difference in the OR when we excluded one study at a time. Sensitivity analysis pooled ORs were depicted in Figure 3. The results show that there was no difference in pooled ORs when we omit one study each time, indicating that our findings were statistically robust. There is no obvious asymmetry in the funnel plot's shape (Figure 4). Furthermore, Egger's test also showed that there is no evidence for publication bias (T vs. M: Egger's test $P = 0.445$; TM+TT versus MM: Egger's test $P = 0.440$; TT versus TM+MM: Egger's test $P = 0.889$).

Discussion

Diabetic nephropathy in diabetes patients is positively correlated with ESRD. DN has a multi-factorial etiology that includes both environmental and genetic factors. RAAS can be activated early in the course of diabetes, causing structural and intraglomerular hemodynamic changes in the diabetic kidney at both the glomerular

Table 1. Baseline characteristics of the AGT M235T studies included in the meta-analysis

| Reference          | Country     | Ethnicity | Genotyping method | HWE P value | Diabetic nephropathy | T2DM |
|--------------------|-------------|-----------|-------------------|-------------|----------------------|------|
| Tomino et al (14)  | Japan       | Asian     | PCR-RFLP          | <0.001      | 0.778                | 507  |
| Doria et al (26)   | USA         | Caucasian | PCR-DGGE          | 0.612       | 42                   | 86   |
| Zychma et al (25)  | Poland      | Caucasian | PCR-DGGE          | 0.778       | 106                  | 228  |
| Fradin et al (19)  | France      | Caucasian | PCR-RFLP          | 0.485       | 25                   | 44   |
| Erglu et al (18)   | Turkey      | Asian     | Melt curve analysis| 0.010       | 10                   | 24   |
| Prasad et al (22)  | India       | Asian     | PCR-RFLP          | 0.086       | 86                   | 86   |
| Osawa et al (21)   | Japan       | Asian     | PCR               | 0.612       | 22                   | 209  |
| Ahluwalia et al (15)| India      | Asian     | PCR-RFLP          | 0.528       | 82                   | 104  |
| Tien et al (16)    | Taiwan      | Asian     | PCR-RFLP          | <0.001      | 17                   | 45   |
| Manea et al (20)   | Romania     | Caucasian | PCR-RFLP          | 0.071       | 17                   | 60   |
| Mitraou et al (17) | Tunisia     | Asian     | PCR-RFLP          | 0.913       | 73                   | 138  |
| Res et al (23)     | Turkey      | Asian     | PCR-RFLP          | 0.049       | 17                   | 68   |
| Shaikh et al (24)  | Pakistan    | Asian     | ARMS-PCR          | 0.612       | 40                   | 28   |
| Makuc et al (13)   | Slovenia    | Caucasian | KASpar            | 0.000       | 57                   | 144  |

Table 2. The association between AGT M235T and DN risk in different genetic models

| Study group         | Allele contrast (T vs. M) | Recessive model (TT vs. TM+MM) | Dominant model (TM+TT vs. MM) |
|---------------------|---------------------------|--------------------------------|-------------------------------|
|                     | OR [95% CI] | P value | OR [95% CI] | P value | OR [95% CI] | P value |
| Overall (14)         | 1.01 [0.75-1.37] | 0.933   | 1.21 [0.80-1.83] | 0.374 | 0.95 [0.66-1.38] | 0.801 |
| Ethnicity            |              |         |              |         |              |         |
| Asian (n=9)          | 1.08 [0.69-1.68] | 0.738   | 1.36 [0.73-2.51] | 0.312 | 1.07 [0.63-1.82] | 0.806 |
| Caucasian (5)        | 0.90 [0.70-1.16] | 0.434   | 0.95 [0.65-1.39] | 0.799 | 0.77 [0.49-1.21] | 0.262 |

Figure 2. Forrest plot of dominant model for overall comparison of AGT M235T polymorphisms and DN.
and tubulointerstitial levels (29,30). Microalbuminuria is considered a risk factor for early-stage DN progression and may occur due to endothelial dysfunction and hyperhomocysteinemia. Approximately one-third of diabetic patients are susceptible to nephrotic disease (31). Poor glycemic control has been identified as one of the major causes of developing nephropathy.

Despite the fact that a family history of DN is one of the most likely indicators of a hereditary genetic predisposition to DN, due to the involvement of multiple genetic and environmental risk factors in the pathogenesis of DN, determining an individual's risk of inheriting nephropathy is difficult. Despite extensive and thorough research efforts, the underlying causative genetic components remain elusive (32-34). The M235T variant has been shown to alter the plasma levels of AGT (35, 36) with increased serum AGT levels for patients with T-allele (37). In addition, there is a positive correlation between AGT M235T genotype and AGT plasma levels in myocardial infarction (MI) (38,39). The present meta-analysis revealed that there was no significant association between AGT M235T and DN risk. We also found that there is a potential heterogeneity between studies. The results of our meta-analysis are in consensus with a previous meta-analysis that provided no evidence of a significant association between AGT M235T polymorphism and DN risk (40). In contrast to this, two independent meta-analyses demonstrated the association between AGT M235T and DN risk in Caucasian (41) and Asian populations (42).

Conclusion
In conclusion, this meta-analysis found no evidence of a link between AGT M235T and DN risk. Since, the majority of the studies in this meta-analysis were Asian and Caucasian, the distribution of AGT M23T varies across ethnic groups and the results cannot be generalised. However, validation of this association will require multi-center and large population-based studies.

Authors’ contribution
BS and SS conducted the primary search. HKV and TPKR and SP participated in methodological search and data collection. BS conducted the draft, LVKSB conducted the primary revisions. SP conducted the secondary edit. LVKSB finalized the manuscript. All authors read and signed the final paper.

Conflicts of interest
The authors declare that they have no competing interests.

Ethical considerations
Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the authors.

Funding/Support
None.

References
1. Chawla A, Chawla R, Jaggi S. Microvascular and macrovascular complications in diabetes mellitus: Distinct or continuum? Indian J Endocrinol Metab. 2016;20:546-51. doi: 10.4103/2230-8210.183480.
2. Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2015;5:49-56.
3. USRDS. 2018 USRDS Annual Data Report: Executive Summary. Am J Kidney Dis. 2019;73:A9-A22. doi: ddoi:10.1053/j.ajkd.2019.01.002.
4. Fu H, Liu S, Bastacky Sl, Wang X, Tian X-J, Zhou D. Diabetic kidney diseases revisited: A new perspective for a new era. Mol Metabol. 2019;30:250-63. doi: 10.1016/j.molmet.2019.10.005.
5. Unnikrishnan R, Anjana RM, Mohan V. Diabetes mellitus and its complications in India. Nat Rev Endocrinol. 2016;12:357-70. doi: 10.1038/nrendo.2016.53.
6. Lakkakula S, Verma HK, Lakkakula BV. The K469E genetic variant in the ICAM1 gene is associated with type 2 diabetes but not with its vascular complications: a meta-analysis. J Nephropharmacol. 2019;9:e16. doi: 3.1038/s41727-020.20.016.
7. Wei L, Xiao Y, Li L, Xiong X, Han Y, Zhu X, et al. The Susceptibility Genes in Diabetic Nephropathy. Kidney Dis. 2018;4:226-37. doi: 10.1159/000492633.
8. Maeda S, Osawa N, Hayashi T, Tsukada S, Kobayashi M,
Kikkawa R. Genetic variations associated with diabetic nephropathy and type II diabetes in a Japanese population. Kidney Int Suppl. 2007;543-8. doi: 10.1038/sj.ki.5002385.

9. Gu HF. Genetic and Epigenetic Studies in Diabetic Kidney Disease. Front Genet. 2019;10:507. doi: 10.3389/fgene.2019.00507.

10. Maezawa Y, Takemoto M, Yokote K. Cell biology of diabetic nephropathy: Roles of endothelial cells, tubulointerstitial cells and podocytes. J Diabet Invest. 2015;6:3-15. doi: 10.1111/jdi.12255.

11. Rahimi Z. The Role of Renin Angiotensin Aldosterone System Genes in Diabetic Nephropathy. Can J Diabetes. 2016;40:178-83. doi: 10.1016/j.cjd.2015.08.016.

12. Lakkakula BV, Khare RL, Verma HK, Pattnaik S. Genetic association of ACE gene I/D polymorphism with the risk of diabetic kidney disease: a meta-analysis. J Nephropathol. 2019;8:e44-e. doi: 10.15171/jnp.2019.44.

13. Makuc J, Seruga M, Završnik M, Cilenšek I, Petrovič D. Angiotensinogens (AGT) gene missense polymorphisms (rs699 and rs4762) and diabetic nephropathy in Croatians with type 2 diabetes mellitus. Bosnian J Basic Med Sci. 2017;17:262-7. doi: 10.17305/bjms.2017.1823.

14. Tomino Y, Makita Y, Shike T, Gohda T, Haneda M, Kikkawa R, et al. Relationships between Polymorphism in the Angiotensinogen, Angiotensin-Converting Enzyme or Angiotensin II Receptor and Renal Progression in Japanese NIDDM Patients. Nephron. 1999;82:139-44. doi: 10.1159/000045390.

15. Aihlulawia TS, Ahuja M, Rai TS, Kohli HS, Bhasanli A, Sud K, et al. ACE variants interact with the RAS pathway to confer risk and protection against type 2 diabetic nephropathy. DNA Cell Biol. 2009;28:141-50. doi: 10.1089/dna.2008.0810.

16. Tien KJ, Hsiao JY, Hsu SC, Liang HT, Lin SR, Chen HC, et al. Gender-Dependent Effect of ACE I/D and AGT M235T Polymorphisms on the Progression of Urinary Albumin Excretion in Taiwanese with Type 2 Diabetes. Am J Nephrol. 2009;29:299-308. doi: 10.1159/0000163592.

17. Mirzaoui N, Ezzidi I, Turki A, Chabi M, Mahjoub T, Almawi WY. Renin-angiotensin-aldosterone system genotypes and haplotypes affect the susceptibility to nephropathy in type 2 diabetes patients. J Renin Angiotensin Aldosterone Syst. 2011;12:572-80. doi: 10.1177/1470321011396542.

18. Eroglu Z, Cetinkalp S, Erdogan M, Kosova B, Karadeniz M, Kutukculer A, et al. Association of the angiotensinogen M235T and angiotensin-converting enzyme insertion/deletion gene polymorphisms in Turkish type 2 diabetic patients with and without nephropathy. J Diabetes Complications. 2008;22:186-90. doi: 10.1016/j.diabcomp.2006.12.004.

19. Fradin S, Goulet-Salmon B, Chantepie M, Grandhomme F, Morello R, Jazouly P, et al. Relationship between polymorphisms in the renin-angiotensin system and nephropathy in type 2 diabetic patients. Diabetes Metab. 2002;28:27-32.

20. Manea SA, Robciuc A, Guica C, Heltianu C. Identification of genetic variants in VOS3, ET-1 and RAS that confer risk and protection against microangiopathy in type 2 diabetic obese subjects. Biochem Biophys Res Commun. 2011;407:486-90. doi: 10.1016/j.bbrc.2011.03.043.

21. Osawa N, Koya D, Araki S-I, Uzu T, Tsunoda T, Kashiwagi A, et al. Combinational effect of genes for the renin–angiotensin system in conferring susceptibility to diabetic nephropathy. J Hum Gen. 2007;52:143-51. doi: 10.1007/s10038-006-0090-9.

22. Prasad P, Tiwari AK, Kumar KMP, Ammini AC, Gupta A, Gupta R, et al. Chronic renal insufficiency among Asian Indians with type 2 diabetes: I. Role of RAAS gene polymorphisms. BMC Med Genet. 2006;7:42-. doi: 10.1186/1471-2350-7-42.

23. Reis KA, Ebinc FA, Koc E, Demirci H, Erten Y, Guz G, et al. Association of the angiotensinogen M235T and APO E gene polymorphisms in Turkish type 2 diabetic patients with and without nephropathy. Ren Fail. 2011;33:469-74. doi: 10.3109/0886022X.2011.568133.

24. Shaikh R, Shahid SM, Mansoor Q, Ismail M, Azhar A. Genetic variants of ACE (Insertion/Deletion) and AGT (M268T) genes in patients with diabetes and nephropathy. J Renin Angiotensin Aldosterone Syst. 2014;15:124-30. doi: 10.1177/1470321013512390.

25. Zychma MJ, Zukowska-Szczechowska E, Lacka BI, Grzeszczak W. Angiotensinogen M235T and chymase gene CMA/B polymorphisms are not associated with nephropathy in type II diabetes. Nephrol Dialysis Transplant. 2000;15:1965-70. doi: 10.1093/ndt/15.12.1965.

26. Doria A, Onuma T, Gueiran G, Freire MBS, Warram JH, Krolewski AS. Angiotensin Polymorphism M235T, Hypertension, and Nephropathy in Insulin-Dependent Diabetes. Hypertension. 1996;27:1134-9. doi: 10.1161/01.HYP.27.5.1134.

27. Cochran WG. The comparison of percentages in matched samples. Biometrika. 1950;37:256-66.

28. Martorell-Marugan J, Toro-Dominguez D, Alarcon-Riquelme ME, Carmona-Saez P. MetaGenyo: a web tool for meta-analysis of genetic association studies. BMC Bioinform. 2017;18:563. doi: 10.1186/s12859-017-1990-4.

29. Al-Rubeaan K, Youssef AM, Subhani SN, Ahmad NA, Al-Shargawi AH, Al-Mutlaq HM, et al. Diabetic nephropathy and its risk factors in a society with a type 2 diabetes epidemic: a Saudi National Diabetes Registry-based study. PloS One. 2014;9:e88956-e. doi: 10.1371/journal.pone.0088956.

30. Tziomalos K, Athyros VG. Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis. Rev Diabet Stud. 2015;12:110-8. doi: 10.1900/RDS.2015.12.110.

31. Shahbazian H, Rezaei I. Diabetic kidney disease; review of the current knowledge. J Renal Inj Prev. 2013;2:73-80. doi: 10.12861/jrip.2013.24.

32. Velayuthan M, Elumalai R, Lakkakula B, Periyasamy S. PPARG genotypes are not a major modifiers of chronic kidney disease progression among the diabetic nephropathy patients. J Ren Endocrinol. 2018;4:e11.

33. Lakkakula S, Kumar Verma H, Gupta P, Lakkakula B. Association between PPARG Pro12Ala polymorphism and diabetic nephropathy risk; an updated meta-analysis of 27 studies. J Renal Endocrinol. 2018;4:e11.

34. Bhaskar LV, Mahin S, Ginila RT, Soundararajan P. Role of the ACE ID and PPARG P12A Polymorphisms in Genetic Factors and Improvements in Diagnosis. Rev Diabet Stud. 2018;4:e11.
(AGT) M235T gene polymorphism and blood pressure in a large, homogeneous study population. J Hum Hypertens. 2003;17:555-9. doi: 10.1038/sj.jhh.1001587.

38. Raygan F, Karimian M, Rezaeian A, Bahmani B, Behjati M. Angiotensinogen-M235T as a risk factor for myocardial infarction in Asian populations: a genetic association study and a bioinformatics approach. Croatian Med J. 2016;57:351-62. doi: 10.3325/cmj.2016.57.351.

39. Pilbrow AP, Palmer BR, Frampton CM, Yandle TG, Troughton RW, Campbell E, et al. Angiotensinogen M235T and T174M gene polymorphisms in combination doubles the risk of mortality in heart failure. Hypertension. 2007;49:322-7. doi: 10.1161/01.HYP.0000253061.30170.68.

40. Ding W, Wang F, Fang Q, Zhang M, Chen J, Gu Y. Association between two genetic polymorphisms of the renin-angiotensin-aldosterone system and diabetic nephropathy: a meta-analysis. Mol Biol Rep. 2012;39:1293-303. doi: 10.1007/s11033-011-0862-7.

41. Zhou B, Wen M, Li L, Hu C-J, Zhang Y, Wang J-T, et al. Associations between angiotensinogen M235T polymorphisms and the risk of diabetic nephropathy: A meta-analysis. Diabet Res Clin Pract. 2018;142:26-36. doi: 10.1016/j.diabres.2018.05.015.

42. Liu N, Wang Y. Association between angiotensinogen T174M polymorphism and the risk of diabetic nephropathy: A meta-analysis. J Renin Angiotensin Aldosterone Syst. 2019;20:1470320318823927. doi: 10.1177/1470320318823927.